

IN THE CLAIMS:

Please cancel claims 47 and 50 without prejudice or disclaimer. Please amend claims 46, 48, 53, and 60 as set forth below. Applicants note that all claims currently pending in the application are shown below for clarity, except claims 47 and 50, which are canceled herein.

Claim 46 (Currently Amended): A dosage form comprising:

a formulation comprising a therapeutic agent;

a first membrane in contact with said formulation [~~, the first membrane being formulated such that the permeability of the first membrane is responsive to changes in osmotic pressure~~];
and

a second membrane [in contact with] positioned over an outside surface of said first membrane, wherein the second membrane is a semipermeable membrane and the first and second membranes are formed such that the first membrane exhibits a permeability responsive to changes in osmotic pressure.

Please cancel claim 47 without prejudice or disclaimer

C2
Claim 48 (Currently Amended): The dosage form of claim 46, wherein said first and second membranes form an internal compartment containing the formulation.

Claim 49: The dosage form of claim 46, wherein the second membrane is formulated to maintain the integrity of the dosage form as the dosage form delivers the therapeutic agent.

Please cancel claim 50 without prejudice or disclaimer.

Claim 51: The dosage form of claim 46, wherein the integrity of the first membrane degrades during operation of the dosage form.

Claim 52: The dosage form of claim 46, wherein the first membrane comprises a hydrophilic substance and a hydrophobic substance.

C3
Claim 53 (Currently Amended): The dosage form of claim 52, wherein the hydrophilicity of the hydrophilic substance [is] changes in response to changes in osmotic pressure.

Claim 54: The dosage form of claim 46, wherein the first membrane is formulated such that the permeability of the first membrane increases in response to a decrease in osmotic pressure.

Claim 55: The dosage form of claim 46, wherein the formulation, the first membrane, and the second membrane are formulated and configured to deliver the therapeutic agent in an extended, non-declining release profile.

Claim 56: The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 30 minutes to about 24 hours.

Claim 57: The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 4 hours to about 24 hours.

Claim 58: The dosage form of claim 46, wherein the formulation, the first membrane, and the second membrane, are formulated and configured to deliver the therapeutic agent in a zero-order release profile.

Claim 59: The dosage form of claim 46, further comprising an expandable layer.

Claim 60 (Currently Amended): A method of delivering a therapeutic agent to a subject, the method comprising:

C⁴

administering a dosage form to the subject, the dosage form comprising a formulation including the therapeutic agent, a first membrane that is in contact with said formulation [~~and exhibits a permeability responsive to changes in osmotic pressure~~], and a second membrane [in contact with] positioned over an outside surface of said first membrane, wherein the second membrane is a semipermeable membrane and the first and second membranes are formed such that the first membrane exhibits a permeability responsive to changes in osmotic pressure.